ARTICLE | Strategy

Beat The Clock

Medicines Co. turns focus from patent disputes to new indications for Angiomax

October 11, 2010 7:00 AM UTC

After years of uncertainty surrounding the patent life for its Angiomax bivalirudin, The Medicines Co. now is pivoting to focus its attention and resources on developing the anticoagulant for additional indications, rather than paying lawyers and lobbyists to persuade lawmakers and agencies to extend the drug's patent life.

The company believes it now will have freedom to operate after the U.S. government chose not to contest a federal court ruling backing Medicine Co.'s argument that the biotech had not missed its deadline to file for a patent term extension for Angiomax...